Attention for medical specialists: PJSC "Kraspharma" has launched to the market the drug Sabviksin (polymyxin B)

The long-awaited new product of 2017 of PJSC "Kraspharma" is the launch of polypeptide antibiotic Sabviksin (polymyxin B).

Nowadays due to the progressive growth of microbial resistance, polymyxins are considered as the basis of "salvation" therapy.

For this reason, Sabviksin due to its direct action regarding multi-resistant gram-negative bacteria provides an effective therapy for infections caused by P. aeruginosa and Acinetobacter spp.

Detailed information about the drug Sabviksin is available at the link..

Back to news list